Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa H S Hillebrandt-Roeffen

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Targeted Oncology|October 26, 2017
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor CeritinibAnke E M van Erp, Melissa H S Hillebrandt-Roeffen, Laurens van Houdt, et al.
Scientific Reports|February 21, 2020
Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcomaJan Marie de Gooyer, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, et al.
Oncotarget|December 22, 2014
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaEmmy D G Fleuren, Melissa H S Hillebrandt-Roeffen, Uta E Flucke, et al.
Cancers|November 16, 2019
Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary AngiosarcomasMarije E Weidema, Uta E Flucke, Winette T A van der Graaf, et al.
Journal of Cancer Research and Clinical Oncology|June 4, 2021
PARP inhibition in UV-associated angiosarcoma preclinical modelsMarije E Weidema, Ingrid M E Desar, Melissa H S Hillebrandt-Roeffen, et al.
Cancers|July 14, 2023
Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 CasesTess Tomassen, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, et al.
Scientific Reports|February 14, 2023
Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5)Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, Marije E Weidema, et al.
Genes, Chromosomes & Cancer|April 30, 2021
Genomic and transcriptomic characterization of desmoplastic small round cell tumorsSaskia Sydow, Yvonne M H Versleijen-Jonkers, Magnus Hansson, et al.
Annals of Surgical Oncology|June 24, 2016
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma PatientsMyrella Vlenterie, Melissa H S Hillebrandt-Roeffen, Esther W M Schaars, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2019
DNA Methylation Profiling Identifies Distinct Clusters in AngiosarcomasMarije E Weidema, Ellen van de Geer, Christian Koelsche, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Targeted Oncology|October 26, 2017
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor CeritinibAnke E M van Erp, Melissa H S Hillebrandt-Roeffen, Laurens van Houdt, et al.
Scientific Reports|February 21, 2020
Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcomaJan Marie de Gooyer, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, et al.
Oncotarget|December 22, 2014
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaEmmy D G Fleuren, Melissa H S Hillebrandt-Roeffen, Uta E Flucke, et al.
Cancers|November 16, 2019
Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary AngiosarcomasMarije E Weidema, Uta E Flucke, Winette T A van der Graaf, et al.
Journal of Cancer Research and Clinical Oncology|June 4, 2021
PARP inhibition in UV-associated angiosarcoma preclinical modelsMarije E Weidema, Ingrid M E Desar, Melissa H S Hillebrandt-Roeffen, et al.
Cancers|July 14, 2023
Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 CasesTess Tomassen, Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, et al.
Scientific Reports|February 14, 2023
Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5)Yvonne M H Versleijen-Jonkers, Melissa H S Hillebrandt-Roeffen, Marije E Weidema, et al.
Genes, Chromosomes & Cancer|April 30, 2021
Genomic and transcriptomic characterization of desmoplastic small round cell tumorsSaskia Sydow, Yvonne M H Versleijen-Jonkers, Magnus Hansson, et al.
Annals of Surgical Oncology|June 24, 2016
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma PatientsMyrella Vlenterie, Melissa H S Hillebrandt-Roeffen, Esther W M Schaars, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2019
DNA Methylation Profiling Identifies Distinct Clusters in AngiosarcomasMarije E Weidema, Ellen van de Geer, Christian Koelsche, et al.
Pageof 2